Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | RECQL | P46063 | 5/20 | 0.65 |
| ▸ | TP53 | P04637 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.65 |
| ▸ | CASP1 | P29466 | 3/20 | 0.65 |
| ▸ | CASP7 | P55210 | 3/20 | 0.65 |
| ▸ | APEX1 | P27695 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396323 | 0.88 | HSD17B10 (0.66) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL120010 | 0.86 | POLH (0.72) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL119937 | 0.85 | MEN1 (0.61) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL29512814 | 0.84 | KDM4E (0.73) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL34716 | 0.84 | KDM4E (0.73) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| Fisetin SCHEMBL4466733 | 0.83 | MEN1 (0.90) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL117967 | 0.82 | MEN1 (0.58) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| Quercetin SCHEMBL4473370 | 0.82 | MEN1 (0.74) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL7685645 | 0.81 | POLH (0.75) | MEN1KMT2AKDM4EMAPTHSD17B10 | |
| SCHEMBL10860655 | 0.81 | POLH (0.75) | MEN1KMT2AKDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009158007-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | claimed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158031-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158007-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | MEN1 4409/4885KMT2A 4599/4885KDM4E 4285/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | MEN1 3687/4885KMT2A 1354/4885KDM4E 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.